Havrdova, E., Cohen, J. A., Horakova, D., Kovarova, I., & Meluzinova, E. (2017). Understanding the positive benefit: Risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. Ther Clin Risk Manag.
Citação norma ChicagoHavrdova, Eva, Jeffrey A. Cohen, Dana Horakova, Ivana Kovarova, and Eva Meluzinova. "Understanding the Positive Benefit: Risk Profile of Alemtuzumab in Relapsing Multiple Sclerosis: Perspectives From the Alemtuzumab Clinical Development Program." Ther Clin Risk Manag 2017.
ציטוט MLAHavrdova, Eva, et al. "Understanding the Positive Benefit: Risk Profile of Alemtuzumab in Relapsing Multiple Sclerosis: Perspectives From the Alemtuzumab Clinical Development Program." Ther Clin Risk Manag 2017.